Impact of Bruton Tyrosine Kinase Inhibitors on Waldenström Macroglobulinemia–Associated Peripheral Neuropathy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Peripheral Neuropathy in the Phase 3 ASPEN Study of Bruton Tyrosine Kinase Inhibitors for Waldenström Macroglobulinemia
Blood Adv 2024 Dec 03;[EPub Ahead of Print], BM Heyman, SS Opat, BE Wahlin, MAA Dimopoulos, JJ Castillo, A Tedeschi, CS Tam, C Buske, RG Owen, V Leblond, J Trotman, G Barnes, WY Chan, J Schneider, H Allewelt, AC Cohen, JV MatousFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.